Chrissian AA, De Silva S, Quan M, Wiltchik E, Patel P, Furukawa B, Rogstad D, Rockwood N, Ho E, Cheek G. Utility of multimodal sampling and testing during advanced bronchoscopy for diagnosing atypical respiratory infections in a Coccidioides-endemic region. J Thorac Dis. 2023 Sep 1;15(9). doi: 10.21037/jtd-23-83
Chen YW, Ni L, Ospina-Forero L. Visualising internal migration flows across local authorities in England and Wales. EPA. 2021 Jun;53(4):616-8. doi: 10.1177/0308518X20968568
Chen YW, Ni L, Xu DL, Yang JB. Visualising regional disparities in the risk of COVID-19 at different phases of lockdown in England. EPA. 2021 Jan 19;53(5):883-6. doi: 10.1177%2F0308518X20984165
Barnett C, Davenport MS, Montgomery JS, Kunju LP, Denton B, Piert M. 18F-choline PET/mpMRI for detection of significant prostate cancer, part 2: cost-effectiveness analysis. J Nucl Med. 2019 Dec;60(12):1705-12. doi: 10.2967/jnumed.119.225771
Davenport MS, Montgomery JS, Kunju LP, Siddiqui J, Shanka PR, Rajendiran T, Shao X, Lee E, Barnett CL, Denton BT, Piert M. 18F-choline PET/mpMRI for detection of clinically significant prostate cancer: Part 1. Improved risk stratification for MRI-guided transrectal prostate biopsies. J Nucl Med. 2019 Aug 16. doi: 10.2967/jnumed.119.225789.
Ling W, Nadipelli VR, Solem CT, Farabee D, Ronquest NA, Perrochet B, Learned SM, Deshpande CG, Heidbreder C. Measuring recovery in opioid use disorder: clinical utility and psychometric properties of the Treatment Effectiveness Assessment. Subst Abuse Rehabil. 2019 Jun 5;10:13-21. doi: 10.2147/SAR.S198361
Ronquest NA, Willson TM, Montejano LB, Nadipelli VR, Wollschlaeger BA. Relationship between buprenorphine adherence and relapse, health care utilization and costs in privately and publicly insured patients with opioid use disorder. Subst Abuse Rehabil. 2018 Sep 21;9:59-78. doi: 10.2147/SAR.S150253
Boscarino JA, Kirchner HL, Pitcavage JM, Nadipelli VR, Ronquest NA, Fitzpatrick MH, Han JJ. Factors associated with opioid overdose: a 10-year retrospective study of patients in a large integrated health care system. Subst Abuse Rehabil. 2016 Sep 16;7:131-41. doi: 10.2147/SAR.S108302
Brogan AJ, Deniz B, Miller JD, Mladsi DM, Herring WL, Thompson JR. Cost-effectiveness assessment of telaprevir combination therapy compared with pegylated interferon and ribavirin alone in the management of chronic hepatitis C virus infection in Canada. Poster presented at the 2012 Canadian Digestive Diseases Week and the Annual Winter Meeting of the Canadian Association for the Study of the Liver; February 24, 2012. Montreal, Canada. [abstract] Can J Gastroenterol. 2012 Feb; 26(Suppl(SA)).